当前位置: 首页 >> 检索结果
261. Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.
作者: Peter Schmid.;Javier Cortes.;Rebecca Dent.;Heather McArthur.;Lajos Pusztai.;Sherko Kümmel.;Carsten Denkert.;Yeon Hee Park.;Rina Hui.;Nadia Harbeck.;Masato Takahashi.;Seock-Ah Im.;Michael Untch.;Peter A Fasching.;Marie-Ange Mouret-Reynier.;Theodoros Foukakis.;Marta Ferreira.;Fatima Cardoso.;Xuan Zhou.;Vassiliki Karantza.;Konstantinos Tryfonidis.;Gursel Aktan.;Joyce O'Shaughnessy.; .
来源: N Engl J Med. 2024年391卷21期1981-1991页
In patients with early-stage triple-negative breast cancer, the phase 3 KEYNOTE-522 trial showed significant improvements in pathological complete response and event-free survival with the addition of pembrolizumab to platinum-containing chemotherapy. Here we report the final results for overall survival.
262. Preoperative Chemoradiotherapy for Resectable Gastric Cancer.
作者: Trevor Leong.;B Mark Smithers.;Michael Michael.;Karin Haustermans.;Rebecca Wong.;Val Gebski.;Rachel L O'Connell.;John Zalcberg.;Alex Boussioutas.;Michael Findlay.;David Willis.;Alisha Moore.;William K Murray.;Florian Lordick.;Chris O'Callaghan.;Carol Swallow.;Gail Darling.;Danielle Miller.;Andrew Strickland.;Moishe Liberman.;Laurent Mineur.;John Simes.; .
来源: N Engl J Med. 2024年391卷19期1810-1821页
In Western countries, the current standard of care for resectable gastric cancer is perioperative chemotherapy. Preoperative chemoradiotherapy has been considered, but data are limited regarding this treatment as compared with perioperative chemotherapy alone.
263. Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma.
作者: Andrea B Apolo.;Karla V Ballman.;Guru Sonpavde.;Stephanie Berg.;William Y Kim.;Rahul Parikh.;Min Yuen Teo.;Randy F Sweis.;Daniel M Geynisman.;Petros Grivas.;Gurkamal Chatta.;Zachery Roger Reichert.;Joseph W Kim.;Mehmet Asim Bilen.;Bradley McGregor.;Parminder Singh.;Abhishek Tripathi.;Suzanne Cole.;Nicholas Simon.;Scot Niglio.;Lisa Ley.;Lisa Cordes.;Sandy Srinivas.;Jiaoti Huang.;Meagan Odegaard.;Colleen Watt.;Daniel Petrylak.;Jeannie Hoffman-Censits.;Yujia Wen.;Olwen Hahn.;Cecilia Mitchell.;Alan Tan.;Howard Streicher.;Elad Sharon.;Helen Moon.;Michael Woods.;Susan Halabi.;Gabriela Perez Burbano.;Michael J Morris.;Jonathan E Rosenberg.
来源: N Engl J Med. 2025年392卷1期45-55页
Muscle-invasive urothelial carcinoma is an aggressive disease with high rates of relapse. Whether pembrolizumab as adjuvant therapy would be effective in patients with high-risk muscle-invasive urothelial carcinoma after radical surgery is unknown.
264. Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.
作者: Jedd D Wolchok.;Vanna Chiarion-Sileni.;Piotr Rutkowski.;C Lance Cowey.;Dirk Schadendorf.;John Wagstaff.;Paola Queirolo.;Reinhard Dummer.;Marcus O Butler.;Andrew G Hill.;Michael A Postow.;Caroline Gaudy-Marqueste.;Theresa Medina.;Christopher D Lao.;John Walker.;Iván Márquez-Rodas.;John B A G Haanen.;Massimo Guidoboni.;Michele Maio.;Patrick Schöffski.;Matteo S Carlino.;Shahneen Sandhu.;Céleste Lebbé.;Paolo A Ascierto.;Georgina V Long.;Corey Ritchings.;Ayman Nassar.;Margarita Askelson.;Melanie Pe Benito.;Wenjia Wang.;F Stephen Hodi.;James Larkin.; .
来源: N Engl J Med. 2025年392卷1期11-22页
Previous results from this trial showed longer overall survival after treatment with nivolumab plus ipilimumab or with nivolumab monotherapy than with ipilimumab monotherapy in patients with advanced melanoma. Given that patients with advanced melanoma are living longer than 7.5 years, longer-term data were needed to address new clinically relevant questions.
265. Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer.
作者: Aditya Bardia.;Xichun Hu.;Rebecca Dent.;Kan Yonemori.;Carlos H Barrios.;Joyce A O'Shaughnessy.;Hans Wildiers.;Jean-Yves Pierga.;Qingyuan Zhang.;Cristina Saura.;Laura Biganzoli.;Joohyuk Sohn.;Seock-Ah Im.;Christelle Lévy.;William Jacot.;Natasha Begbie.;Jun Ke.;Gargi Patel.;Giuseppe Curigliano.; .
来源: N Engl J Med. 2024年391卷22期2110-2122页
Outcomes in patients with hormone receptor-positive metastatic breast cancer worsen after one or more lines of endocrine-based therapy. Trastuzumab deruxtecan has shown efficacy in patients with metastatic breast cancer with low expression of human epidermal growth factor receptor 2 (HER2) after previous chemotherapy.
266. Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer.
作者: Ying Cheng.;David R Spigel.;Byoung Chul Cho.;Konstantin K Laktionov.;Jian Fang.;Yuanbin Chen.;Yoshitaka Zenke.;Ki Hyeong Lee.;Qiming Wang.;Alejandro Navarro.;Reyes Bernabe.;Eva Lotte Buchmeier.;John Wen-Cheng Chang.;Yoshimasa Shiraishi.;Sema Sezgin Goksu.;Andrzej Badzio.;Anhui Shi.;Davey B Daniel.;Nguyen Thi Thai Hoa.;Milada Zemanova.;Helen Mann.;Hema Gowda.;Haiyi Jiang.;Suresh Senan.; .
来源: N Engl J Med. 2024年391卷14期1313-1327页
Adjuvant therapy with durvalumab, with or without tremelimumab, may have efficacy in patients with limited-stage small-cell lung cancer who do not have disease progression after standard concurrent platinum-based chemoradiotherapy.
267. Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial.
作者: Claudia K Fox.;Margarita Barrientos-Pérez.;Eric M Bomberg.;John Dcruz.;Inge Gies.;Nina M Harder-Lauridsen.;Muhammad Yazid Jalaludin.;Kushal Sahu.;Petra Weimers.;Thomas Zueger.;Silva Arslanian.; .
来源: N Engl J Med. 2025年392卷6期555-565页
No medications are currently approved for the treatment of nonmonogenic, nonsyndromic obesity in children younger than 12 years of age. Although the use of liraglutide has been shown to induce weight loss in adults and adolescents with obesity, its safety and efficacy have not been established in children.
268. Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment.
作者: Carol Wysham.;Harpreet S Bajaj.;Stefano Del Prato.;Denise Reis Franco.;Arihiro Kiyosue.;Dominik Dahl.;Chunmei Zhou.;Molly C Carr.;Michael Case.;Livia Firmino Gonçalves.; .
来源: N Engl J Med. 2024年391卷23期2201-2211页
Insulin efsitora alfa (efsitora) is a new basal insulin designed for once-weekly administration. Data on safety and efficacy have been limited to small, phase 1 or phase 2 trials.
269. Long-Term Oxygen Therapy for 24 or 15 Hours per Day in Severe Hypoxemia.
作者: Magnus Ekström.;Anders Andersson.;Savvas Papadopoulos.;Taivo Kipper.;Bo Pedersen.;Ozren Kricka.;Pierre Sobrino.;Michael Runold.;Andreas Palm.;Anders Blomberg.;Ranjh Hamed.;Eva Lindberg.;Björn Sundberg.;Nermin Hadziosmanovic.;Filip Björklund.;Christer Janson.;Christine F McDonald.;David C Currow.;Josefin Sundh.; .
来源: N Engl J Med. 2024年391卷11期977-988页
Long-term oxygen supplementation for at least 15 hours per day prolongs survival among patients with severe hypoxemia. On the basis of a nonrandomized comparison, long-term oxygen therapy has been recommended to be used for 24 hours per day, a more burdensome regimen.
270. Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype.
作者: David J Jackson.;Michael E Wechsler.;Daniel J Jackson.;David Bernstein.;Stephanie Korn.;Paul E Pfeffer.;Ruchong Chen.;Junpei Saito.;Gustavo de Luíz Martinez.;Lucyna Dymek.;Loretta Jacques.;Nicholas Bird.;Stein Schalkwijk.;Douglas Smith.;Peter Howarth.;Ian D Pavord.; .; .; .
来源: N Engl J Med. 2024年391卷24期2337-2349页
Depemokimab is an ultra-long-acting biologic therapy with enhanced binding affinity for interleukin-5 that may enable effective 6-month dosing intervals.
271. Adjunctive Intravenous Argatroban or Eptifibatide for Ischemic Stroke.
作者: Opeolu Adeoye.;Joseph Broderick.;Colin P Derdeyn.;James C Grotta.;William Barsan.;Oladi Bentho.;Scott Berry.;Mauricio Concha.;Iris Davis.;Stacie Demel.;Jordan Elm.;Nina Gentile.;Todd Graves.;Melissa Hoffman.;Josephine Huang.;James Ingles.;Scott Janis.;Adam S Jasne.;Pooja Khatri.;Steven R Levine.;Aniel Majjhoo.;Peter Panagos.;Arthur Pancioli.;Stephanie Pizzella.;Tamra Ranasinghe.;Noor Sabagha.;Sanjeev Sivakumar.;Christopher Streib.;Achala Vagal.;Alastair Wilson.;Max Wintermark.;Albert J Yoo.;Andrew D Barreto.
来源: N Engl J Med. 2024年391卷9期810-820页
Intravenous thrombolysis is a standard treatment of acute ischemic stroke. The efficacy and safety of combining intravenous thrombolysis with argatroban (an anticoagulant agent) or eptifibatide (an antiplatelet agent) are unclear.
272. A Monoclonal Antibody to PACAP for Migraine Prevention.
作者: Messoud Ashina.;Ravinder Phul.;Melanie Khodaie.;Elin Löf.;Ioana Florea.
来源: N Engl J Med. 2024年391卷9期800-809页
Targeting pituitary adenylate cyclase-activating polypeptide (PACAP) is a new avenue for treating migraine. The efficacy and safety of intravenous Lu AG09222, a humanized monoclonal antibody directed against the PACAP ligand, for migraine prevention are unclear.
273. Doxorubicin-Trabectedin with Trabectedin Maintenance in Leiomyosarcoma.
作者: Patricia Pautier.;Antoine Italiano.;Sophie Piperno-Neumann.;Christine Chevreau.;Nicolas Penel.;Nelly Firmin.;Pascaline Boudou-Rouquette.;François Bertucci.;Valérie Lebrun-Ly.;Isabelle Ray-Coquard.;Elsa Kalbacher.;Emmanuelle Bompas.;Olivier Collard.;Nicolas Isambert.;Cécile Guillemet.;Maria Rios.;Axel Le Cesne.;Corinne Balleyguier.;Baptiste Archambaud.;Florence Duffaud.; .
来源: N Engl J Med. 2024年391卷9期789-799页
The addition of trabectedin to doxorubicin, followed by trabectedin maintenance, may have superior efficacy to doxorubicin alone as first-line treatment in patients with advanced leiomyosarcoma.
274. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.
作者: Scott D Solomon.;John J V McMurray.;Muthiah Vaduganathan.;Brian Claggett.;Pardeep S Jhund.;Akshay S Desai.;Alasdair D Henderson.;Carolyn S P Lam.;Bertram Pitt.;Michele Senni.;Sanjiv J Shah.;Adriaan A Voors.;Faiez Zannad.;Imran Zainal Abidin.;Marco Antonio Alcocer-Gamba.;John J Atherton.;Johann Bauersachs.;Ma Chang-Sheng.;Chern-En Chiang.;Ovidiu Chioncel.;Vijay Chopra.;Josep Comin-Colet.;Gerasimos Filippatos.;Cândida Fonseca.;Grzegorz Gajos.;Sorel Goland.;Eva Goncalvesova.;Seokmin Kang.;Tzvetana Katova.;Mikhail N Kosiborod.;Gustavs Latkovskis.;Alex Pui-Wai Lee.;Gerard C M Linssen.;Guillermo Llamas-Esperón.;Vyacheslav Mareev.;Felipe A Martinez.;Vojtěch Melenovský.;Béla Merkely.;Savina Nodari.;Mark C Petrie.;Clara Inés Saldarriaga.;Jose Francisco Kerr Saraiva.;Naoki Sato.;Morten Schou.;Kavita Sharma.;Richard Troughton.;Jacob A Udell.;Heikki Ukkonen.;Orly Vardeny.;Subodh Verma.;Dirk von Lewinski.;Leonid Voronkov.;Mehmet Birhan Yilmaz.;Shelley Zieroth.;James Lay-Flurrie.;Ilse van Gameren.;Flaviana Amarante.;Peter Kolkhof.;Prabhakar Viswanathan.; .
来源: N Engl J Med. 2024年391卷16期1475-1485页
Steroidal mineralocorticoid receptor antagonists reduce morbidity and mortality among patients with heart failure and reduced ejection fraction, but their efficacy in those with heart failure and mildly reduced or preserved ejection fraction has not been established. Data regarding the efficacy and safety of the nonsteroidal mineralocorticoid receptor antagonist finerenone in patients with heart failure and mildly reduced or preserved ejection fraction are needed.
275. Invasive Treatment Strategy for Older Patients with Myocardial Infarction.
作者: Vijay Kunadian.;Helen Mossop.;Carol Shields.;Michelle Bardgett.;Philippa Watts.;M Dawn Teare.;Jonathan Pritchard.;Jennifer Adams-Hall.;Craig Runnett.;David P Ripley.;Justin Carter.;Julie Quigley.;Justin Cooke.;David Austin.;Jerry Murphy.;Damian Kelly.;James McGowan.;Murugapathy Veerasamy.;Dirk Felmeden.;Hussain Contractor.;Sanjay Mutgi.;John Irving.;Steven Lindsay.;Gavin Galasko.;Kelvin Lee.;Ayyaz Sultan.;Amardeep G Dastidar.;Shazia Hussain.;Iftikhar Ul Haq.;Mark de Belder.;Martin Denvir.;Marcus Flather.;Robert F Storey.;David E Newby.;Stuart J Pocock.;Keith A A Fox.; .
来源: N Engl J Med. 2024年391卷18期1673-1684页
Whether a conservative strategy of medical therapy alone or a strategy of medical therapy plus invasive treatment is more beneficial in older adults with non-ST-segment elevation myocardial infarction (NSTEMI) remains unclear.
276. Asundexian versus Apixaban in Patients with Atrial Fibrillation.
作者: Jonathan P Piccini.;Manesh R Patel.;Jan Steffel.;Keith Ferdinand.;Isabelle C Van Gelder.;Andrea M Russo.;Chang-Sheng Ma.;Shaun G Goodman.;Jonas Oldgren.;Christopher Hammett.;Renato D Lopes.;Masaharu Akao.;Raffaele De Caterina.;Paulus Kirchhof.;Diana A Gorog.;Martin Hemels.;Michiel Rienstra.;W Schuyler Jones.;Josephine Harrington.;Gregory Y H Lip.;Stephen J Ellis.;Frank W Rockhold.;Christoph Neumann.;John H Alexander.;Thomas Viethen.;James Hung.;Rosa Coppolecchia.;Hardi Mundl.;Valeria Caso.; .
来源: N Engl J Med. 2025年392卷1期23-32页
Stroke prevention with direct-acting oral anticoagulant agents in patients with atrial fibrillation confers a risk of bleeding and limits their use. Asundexian, an activated factor XI (XIa) inhibitor, is an oral anticoagulant that may prevent strokes with less bleeding.
277. Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk.
作者: Gerald F Watts.;Robert S Rosenson.;Robert A Hegele.;Ira J Goldberg.;Antonio Gallo.;Ann Mertens.;Alexis Baass.;Rong Zhou.;Ma'an Muhsin.;Jennifer Hellawell.;Nicholas J Leeper.;Daniel Gaudet.; .
来源: N Engl J Med. 2025年392卷2期127-137页
Persistent chylomicronemia is a genetic recessive disorder that is classically caused by familial chylomicronemia syndrome (FCS), but it also has multifactorial causes. The disorder is associated with the risk of recurrent acute pancreatitis. Plozasiran is a small interfering RNA that reduces hepatic production of apolipoprotein C-III and circulating triglycerides.
278. Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease.
作者: Min Soo Cho.;Do-Yoon Kang.;Jung-Min Ahn.;Sung-Cheol Yun.;Yong-Seog Oh.;Chang Hoon Lee.;Eue-Keun Choi.;Ji Hyun Lee.;Chang Hee Kwon.;Gyung-Min Park.;Hyung Oh Choi.;Kyoung-Ha Park.;Kyoung-Min Park.;Jongmin Hwang.;Ki-Dong Yoo.;Young-Rak Cho.;Ji Hyun Kim.;Ki Won Hwang.;Eun-Sun Jin.;Osung Kwon.;Ki-Hun Kim.;Seung-Jung Park.;Duk-Woo Park.;Gi-Byoung Nam.; .
来源: N Engl J Med. 2024年391卷22期2075-2086页
Despite consistent recommendations from clinical guidelines, data from randomized trials on a long-term antithrombotic treatment strategy for patients with atrial fibrillation and stable coronary artery disease are still lacking.
279. Continuation versus Interruption of Oral Anticoagulation during TAVI.
作者: Dirk Jan van Ginkel.;Willem L Bor.;Hugo M Aarts.;Christophe Dubois.;Ole De Backer.;Maxim J P Rooijakkers.;Liesbeth Rosseel.;Leo Veenstra.;Frank van der Kley.;Kees H van Bergeijk.;Nicolas M Van Mieghem.;Pierfrancesco Agostoni.;Michiel Voskuil.;Carl E Schotborgh.;Alexander J J IJsselmuiden.;Jan A S Van Der Heyden.;Renicus S Hermanides.;Emanuele Barbato.;Darren Mylotte.;Enrico Fabris.;Peter Frambach.;Karl Dujardin.;Bert Ferdinande.;Joyce Peper.;Benno J W M Rensing.;Leo Timmers.;Martin J Swaans.;Jorn Brouwer.;Vincent J Nijenhuis.;Daniel C Overduin.;Tom Adriaenssens.;Yusuke Kobari.;Pieter A Vriesendorp.;Jose M Montero-Cabezas.;Hicham El Jattari.;Jonathan Halim.;Ben J L Van den Branden.;Remigio Leonora.;Marc Vanderheyden.;Michael Lauterbach.;Joanna J Wykrzykowska.;Arnoud W J van 't Hof.;Niels van Royen.;Jan G P Tijssen.;Ronak Delewi.;Jurriën M Ten Berg.; .; .
来源: N Engl J Med. 2025年392卷5期438-449页
One third of patients undergoing transcatheter aortic-valve implantation (TAVI) have an indication for oral anticoagulation owing to concomitant diseases. Interruption of oral anticoagulation during TAVI may decrease the risk of bleeding, whereas continuation may decrease the risk of thromboembolism.
280. PCI in Patients Undergoing Transcatheter Aortic-Valve Implantation.
作者: Jacob Lønborg.;Reza Jabbari.;Muhammad Sabbah.;Karsten T Veien.;Matti Niemelä.;Phillip Freeman.;Rickard Linder.;Dan Ioanes.;Christian J Terkelsen.;Olli A Kajander.;Sasha Koul.;Mikko Savontaus.;Pasi Karjalainen.;Andrejs Erglis.;Mikko Minkkinen.;Rikke Sørensen.;Hans-Henrik Tilsted.;Lene Holmvang.;Gintautas Bieliauskas.;Julia Ellert.;Jarkko Piuhola.;Ashkan Eftekhari.;Oskar Angerås.;Andreas Rück.;Evald H Christiansen.;Troels Jørgensen.;Burcu T Özbek.;Charlotte Glinge.;Lars Søndergaard.;Ole De Backer.;Thomas Engstrøm.; .
来源: N Engl J Med. 2024年391卷23期2189-2200页
The benefit of percutaneous coronary intervention (PCI) in patients with stable coronary artery disease and severe aortic stenosis who are undergoing transcatheter aortic-valve implantation (TAVI) remains unclear.
|